Foreign Matter Analysis: Introduction

COMPREHENSIVE | PRECISE | RELIABLE

Protecting your pharmaceutical or biopharmaceutical business from foreign matter contamination is vital.

What is Foreign Particulate Matter?

Foreign matter is any material or residue that is not meant to be in the product.

The United States Pharmacopoeia Ch. 788 defines Particulate Matter (in injections) as “mobile undissolved particles, other than gas bubbles, unintentionally present in the solutions.”

The Impact of Foreign Particulate Matter?

FPM contamination can have a devastating impact on product quality, safety, and efficacy.

This can lead to costly product recalls, delays in development or production, regulatory penalties, and damage to your reputation.

Why Outsource Foreign Matter Analysis?

  1. Rapid response to unpredictable contamination events
  2. Advanced analytical tools for trace-level foreign matter analysiss.
  3. Data interpretation and route cause from vast experience and expertise
  4. A central dedicated support lab for your global manufacturing locations

Resolian contains a team of seasoned experts, with decades of experience.

  • Audited by the FDA (US) and the MHRA (UK)
  • Home Office controlled substance license

Typical Contaminates Identified in Studies Include

  • Fibres
  • Metallic particles
  • Glass shards and delamination
  • Microplastics and polymers
  • Lubricant droplets
  • Corrosion products
  • Smears and stains
  • Residues and precipitates
  • Agglomeration
  •  

Your product’s integrity and safety are our top priorities.

  1. Protect your patients from the risks of contaminated products
  2. Ensure regulatory compliance
  3. Maintain product quality
  4. Achieve batch consistency
  5. Improve cost efficiency
  6. Protect your supply chain
  7. Support your research and development efforts
Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.